In solution-phase peptide API workflows, Cbz-L-serine (CAS 1145-80-8) is handled as an N-protected chiral building block with an unprotected primary hydroxyl. GMP release specifications typically require HPLC purity ≥99.0% by area at 210 nm, chiral purity ≥99.5%, loss on drying ≤0.5%, and residual solvents within ICH Q3C(R8) limits. The carboxyl is activated in a 500 L glass-lined reactor at 0–5 °C using EDC·HCl at 1.05 molar equivalents and HOBt monohydrate at 1.05 molar equivalents in anhydrous DMF; DIPEA is added to maintain apparent solution pH 8.2–8.5. The jacket set point is held at 2 °C with ±1 °C control because O-acylated impurity increases from 0.3% to 1.8% when batch temperature rises to 12 °C. Activation is limited to 12–18 min before addition of the amino component. Coupling completion is confirmed by HPLC at 220 nm using system suitability criteria from USP <621>, with residual Cbz-L-serine ≤0.5% and D-enantiomer ≤0.1%. Work-up uses ethyl acetate/water partition, sequential washes with 5% citric acid and 0.5 M sodium bicarbonate, and vacuum concentration below 35 °C. The Cbz group is removed by hydrogenolysis over 5% palladium on carbon at 1–3 bar hydrogen in methanol/THF. Ethyl acetate is dried to ≤500 ppm and DMF to ≤880 ppm before the fragment enters subsequent API steps. This route supplies protected dipeptide and tripeptide fragments for serine-containing peptide APIs under ICH Q7.

Converting Cbz-L-serine into N-Cbz-2,2-dimethyloxazolidine-4-carboxylic Acid

For chiral-pool synthesis of Garner’s aldehyde and related oxazolidine intermediates, Cbz-L-serine is first acetalized. A typical charge uses Cbz-L-serine in acetone at 1.0 M, 2.5 molar equivalents of 2,2-dimethoxypropane, and 0.05 molar equivalents of p-toluenesulfonic acid monohydrate. The batch is stirred at 20–25 °C for 10–14 h; conversion is monitored by TLC and confirmed by HPLC at 210 nm, with residual Cbz-L-serine ≤0.5%. Neutralization with solid NaHCO₃ and extraction into ethyl acetate gives N-Cbz-2,2-dimethyloxazolidine-4-carboxylic acid in 90–95% isolated yield. Reduction to the corresponding alcohol is performed with LiAlH₄ in THF at -10–0 °C, or by sodium borohydride reduction via the mixed anhydride when residual aluminium must be avoided. Oxidation to Garner’s aldehyde is carried out with Dess–Martin periodinane in dichloromethane at 20 °C or with TEMPO/NaOCl in dichloromethane/water at 0 °C. The aldehyde is moisture-sensitive and is stored under argon at -20 °C for a maximum of 24 h before use; bench-top exposure at 50% relative humidity produces hydrate formation above 2% within 4 h. Optical purity of the oxazolidine acid is controlled by chiral HPLC to ≥99.0% enantiomeric excess. Terminal downstream products include chiral sphingosine and ceramide intermediates, statine-type transition-state mimetics, and α-amino aldehydes for medicinal chemistry.

What Limits the β-Lactone Route to β-Substituted L-Alanine Derivatives?

The conversion of Cbz-L-serine to its β-lactone proceeds by intramolecular Mitsunobu cyclization in anhydrous THF. Triphenylphosphine at 1.2 molar equivalents and diisopropyl azodicarboxylate at 1.2 molar equivalents are added sequentially at -20 to -10 °C under nitrogen, with Cbz-L-serine held at 0.15 M. Cbz-L-serine is pre-dried at 40 °C under vacuum for 12 h when ambient relative humidity exceeds 60%. The critical process parameter is water content; Karl Fischer titration of the THF and Cbz-L-serine feed must show ≤0.05% water. When moisture exceeds 0.10%, β-lactone hydrolysis to starting material becomes measurable and can reduce yield by 8–15% within 1 h. The reaction is quenched with saturated NH₄Cl, and the product is extracted into dichloromethane. On 1–5 kg scale, triphenylphosphine oxide removal by trituration or flash chromatography is the rate-limiting unit operation; residual triphenylphosphine oxide in the β-lactone must be ≤0.1% for subsequent ring-opening. Ring-opening with soft nucleophiles is conducted at -40 to 0 °C in THF or toluene to yield N-Cbz-protected β-substituted L-alanine derivatives, with enantiomeric excess typically ≥98.0% by chiral HPLC. The β-lactone itself has limited ambient stability and is used within 6 h of isolation. This route supports non-proteinogenic amino acid fragments for protease inhibitor and kinase inhibitor programs. Published data for less common nucleophile classes in this specific configuration is limited; impurity profiles must be established on a per-run basis.

Depsipeptide and O-Acyl Serine Intermediates

O-Acylation of the unprotected hydroxyl in Cbz-L-serine is performed in dichloromethane or THF with pyridine as acid scavenger. The acyl chloride or anhydride is charged at 1.05–1.10 molar equivalents relative to Cbz-L-serine, and pyridine is charged at 1.2 molar equivalents. The jacket is held at 0–5 °C during addition and for 2–4 h; the reaction is considered complete when HPLC shows starting material ≤0.5%. Carboxyl acylation is suppressed by maintaining the carboxylic acid below 1.0 equivalent of tertiary-amine counterion rather than pre-forming a carboxylate salt. The resulting O-acyl Cbz-L-serine is coupled to α-hydroxy acid esters or amino alcohols using DCC/DMAP in dichloromethane at 0–10 °C. Because the O-acyl ester linkage is base-sensitive, extraction washes should not exceed pH 8.0; prolonged washing with 0.5 M NaHCO₃ can cleave the ester at 2–5% per hour. The downstream products are depsipeptide precursors and cyclic depsipeptide fragments. Terminal solids are dried under vacuum at 30 °C to avoid thermal rearrangement. Compliance for intermediates exported to peptide API manufacturing follows ICH Q7, with residual solvent limits under ICH Q3C(R8). EU shipments of the intermediate are documented under REACH import exemption principles for isolated chemical intermediates.

Cbz-L-serine methyl ester is prepared by thionyl chloride-mediated esterification in methanol at -5 to 0 °C. Thionyl chloride is added to anhydrous methanol before Cbz-L-serine at 1.2 molar equivalents; methanol water content by Karl Fischer should be ≤0.1%. The reaction reaches complete conversion within 2–4 h and is quenched by concentration below 25 °C. The crude ester is then dissolved in DMF, and O-silylation is performed with tert-butyldimethylsilyl chloride at 1.1 molar equivalents and imidazole at 1.5 molar equivalents at 20–25 °C for 8–12 h. Work-up with ethyl acetate/water removes DMF and imidazole; residual silyl chloride is hydrolysed and not detected by TLC. The resulting O-TBS-Cbz-L-serine methyl ester serves as a C-terminal building block where the methyl ester is retained for final ester hydrolysis. This intermediate is used in peptide fragment assembly when orthogonal protection of the serine hydroxyl is required. Batch-to-batch variance in methyl ester moisture content is controlled by vacuum drying at 30 °C to loss on drying ≤0.2%. Downstream peptides are released under ICH Q7 for GMP intermediates, and residual methanol is controlled below 3000 ppm under ICH Q3C(R8).

When Cbz-L-serine Fragments Are Condensed onto Resin-Bound Peptide Chains

In fragment condensation on solid support, Cbz-protected serine-containing peptide fragments are prepared in solution, purified, and then activated for coupling to resin-bound peptide chains. The Cbz group is stable to the mildly acidic conditions of 2-chlorotrityl chloride resin loading but is removed only by hydrogenolysis or strongly acidic HBr/AcOH; therefore, the strategy is used when the final peptide contains no other hydrogenation-sensitive functionality. Activation uses HATU at 1.05 molar equivalents and DIPEA at 2.0 molar equivalents in DMF at 20 °C; the fragment is coupled at 2.0 molar equivalents relative to resin loading. Residual piperidine from previous Fmoc deprotection must be ≤0.05%, because excess piperidine consumes the activated ester and lowers coupling efficiency. Coupling is monitored by Kaiser test and by cleavage of a small resin aliquot with 1% TFA in dichloromethane, followed by HPLC. Double coupling is performed if residual free amine is above 0.1 mmol/g. The Cbz group is removed on-resin using HBr/AcOH at 0 °C for 60 min, with thioanisole at 5% v/v as scavenger to minimize benzyl cation alkylation of electron-rich residues. Resin shrinkage in HBr/AcOH is significant; batch records show bed volume reduction up to 15%, requiring slower agitation at 40–60 rpm. Terminal peptide amides and acids are released with simultaneous side-chain deprotection, then purified by preparative RP-HPLC. This approach is used for serine-containing peptides where solution-phase fragment assembly improves purity compared with stepwise SPPS when aggregation-prone sequences are present.